Insights on the Worldwide Liquid Biopsy Market to 2024 - by Cancer Type and by Usage Type -

DUBLIN--()--The "Liquid Biopsy Markets by Cancer Type and by Usage Type with Impact of COVID-19 Pandemic. Including Executive and Consultant Guides and Customized Forecasting and Analysis 2020-2024" report has been added to's offering.

The Screening, Diagnostic, Therapy Selection, Recurrence Monitoring and Screening Market Potential are all explored in this report. What is the impact of the COVID pandemic on the Liquid Biopsy market? This report provides detailed analysis.

Circulating Tumor Cells? Cell-Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find opportunities and pitfalls. Understand growth expectations and the ultimate potential market size.

A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology has created the possibility of widespread screening for all types of cancers with a blood test.

GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The company is now working on a 10,000-plus subject study, called the Circulating Cell-Free Genome Atlas (CCGA) to help identify cancer early. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures.

The market is still in its infancy but has just moved out of the development phase and into the growth phase. The impact on the health care industry is enormous. The report forecasts the market size out to 2024. In addition, the report looks at potential market sizes by country, by cancer and by the four types of usage: screening, diagnosis, therapy selection and recurrence monitoring.

The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate, Cervical, and Other Cancers as well as breakouts by Screening/Early Detection, Diagnostic, Therapy Monitoring and Recurrence Monitoring.

Key Topics Covered:

1. Introduction and Market Definition

2. Market Overview

2.1 Players in a Dynamic Market

2.2 Using Biopsies

2.3 Biopsy Sites

2.4 The Situation Today - Biopsy Analysis

2.5 Evidence of Cancer - Liquid Biopsy Technology

2.6 Cancer Treatment Protocol Under Siege

2.7 Structure of Industry Plays a Part

3. Market Trends

3.1 Factors Driving Growth

3.1.1 Non-Invasive Game Changer

3.1.2 Lower Cost

3.1.3 Greater Accuracy

3.1.4 Wide Range of Potential Uses

3.1.5 Aging Population

3.2 Factors Limiting Growth

3.2.1 Lower prices

3.2.2 Lack of Standards

3.2.3 Protocol Resistance

3.2.4 Initial Adoption Cost

3.2.5 COVID-19

3.3 Instrumentation and Automation

3.3.1 Instruments Key to Market Share

3.3.2 Bioinformatics Plays a Role

3.4 Diagnostic Technology Development

3.4.1 Next Generation Sequencing Fuels a Revolution

3.4.2 Impact of NGS on pricing

3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment

3.4.4 CGES Testing, A Brave New World

3.4.5 Biochips/Giant magnetoresistance based assay

4. Liquid Biopsy Recent Developments

4.1 Recent Developments - Importance and How to Use This Section

4.1.1 Importance of These Developments

4.1.2 How to Use This Section

5. Profiles of Key Players

6. The Global Market for Liquid Biopsy Diagnostics

6.1 Global Market Overview by Country

6.2 Global Market by Cancer - Overview

6.3 Global Market by Usage - Overview

7. Global Liquid Biopsy Diagnostic Markets - By Cancer

7.1 Breast

7.2 Colorectal

7.3 Cervical

7.4 Lung

7.5 Prostate

7.6 Other

8. Global Liquid Biopsy Diagnostic Markets - by Usage

8.1 Screening

8.2 Diagnostic

8.3 Therapy

8.4 Monitor

Companies Mentioned

  • Abbott Diagnostics
  • AccuraGen Inc
  • Acuamark Diagnostics
  • Admera Health, LLC
  • Agena Bioscience, Inc
  • Agilent
  • Amoy Diagnostics Co., Ltd.
  • Anchor Dx
  • ANGLE plc
  • ApoCell, Inc.
  • ArcherDx, Inc
  • Asuragen
  • AVIVA Biosciences
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bio-Rad Laboratories, Inc
  • Bio-Techne
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc
  • Biodesix Inc
  • BioFluidica
  • bioMrieux Diagnostics
  • Bioneer Corporation
  • Bioview
  • Bolidics
  • Boreal Genomics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Cepheid (now Danaher)
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp
  • CytoTrack
  • Datar Cancer Genetics Limited
  • Diagenode Diagnostics
  • Diagnologix LLC
  • Enzo Life Sciences, Inc
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Exosome Diagnostics
  • Exosome Sciences
  • Fluidigm Corp
  • Fluxion Biosciences
  • And Many More Companies!

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900